Compare iShares MSCI Germany (DAX) (EWG) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs Cassava Sciences Inc — how do they compare? iShares MSCI Germany (DAX) trades at $40.96 (market cap $1.42B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: iShares MSCI Germany (DAX) is far larger — about 36× Cassava Sciences Inc's market cap, and iShares MSCI Germany (DAX) is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Germany (DAX) for 54 Days and Cassava Sciences Inc for 37 Days on average.
| EWG | FLNA | |
|---|---|---|
Market Cap | $1.42B | $39.40M |
Volume | 1,110,573 | 759,018 |
Sector | Broad Market / Factor | Health |
52-Week High | $44.59 | $4.64 |
52-Week Low | $38.08 | $0.68 |
Typical Hold Time | 54 Days | 37 Days |
Enterprise Value | — | -$43.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG is trading at $40.67, down 0.59% with a bearish technical outlook as moving averages and oscillators signal selling pressure. The stock faces resistance at $41 with support at $40. Recent European market news highlights ECB rate hikes and energy price concerns affecting regional equities, though some analysts note resilience in European stocks despite macroeconomic pressures.
The bearish technical indicators and European economic uncertainty create near-term headwinds. Investment opportunity exists if the stock holds above $40 support, but risks include further ECB tightening and energy-driven inflation. Upside potential requires breaking above $41 resistance with improved market sentiment toward European equities.
FLNA trades at $0.8136, down 0.26% with a bearish technical signal. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent positive FDA news regarding the clinical hold lift on simufilam for epilepsy research provides a potential catalyst. Cash flow remains negative with net cash flow of -$33.07M in 2025.
The outlook is mixed with strong analyst support (66.7% buy ratings) against fundamental challenges. Investment opportunity lies in clinical trial success, while risks include sustained cash burn and execution hurdles. The stock's low EV/EBITDA of 1.03 and P/B of 0.62 suggest undervaluation if pipeline milestones are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
